NeuroSense seeks US patent for PrimeC in traumatic brain injury

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) said on October 19, 2026 that it filed a patent application with the U.S. Patent and Trademark Office for methods of treating traumatic brain injury and related central nervous system injuries using a combination of ciprofloxacin and celecoxib, the active ingredients in its drug candidate PrimeC.¹

The filing is broad in scope. It covers treatment of brain injuries ranging from concussion and mild TBI to moderate and severe TBI, including blast-related injury, and their long-term effects such as chronic traumatic encephalopathy (CTE).¹ If the patent is granted, the company expects protection to run through 2047, subject to any extensions.¹

NeuroSense framed the move against a large unmet need. The company said TBI affects millions of people worldwide each year and that no approved disease-modifying therapies currently target the secondary neurological injury that follows TBI.¹ It noted that TBI can trigger neuroinflammation, oxidative stress and progressive neuronal damage, mechanisms that overlap with pathways seen in neurodegenerative disorders.¹

The company described the filing as part of a longer-term strategy. NeuroSense said the patent application supports its plan to pursue additional uses for PrimeC beyond its current programs and views TBI as a way to expand PrimeC's commercial potential.¹ The company said ALS remains its main development priority, while it evaluates future TBI research through possible collaborations, grants, and other non-dilutive funding.¹

CEO Alon Ben-Noon said in the release, "While ALS remains our primary focus, we believe PrimeC may have potential across a broader range of neurological conditions that share common underlying disease mechanisms. TBI is a particularly compelling area given the large affected population, the long-term consequences of brain injury and the lack of approved disease-modifying treatments."¹

NeuroSense separately noted that it has received FDA clearance to begin its pivotal Phase 3 PARAGON trial in ALS, to be conducted primarily in the United States.¹